ノースカロライナにおける自己免疫疾患の臨床試験
ノースカロライナ内の拠点で、自己免疫疾患に関する18件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Environmental Risk Factors for the Anti-synthetase Syndrome
- NIEHS Clinical Research Unit (CRU), Research Triangle Park
被験者募集中観察研究健康なボランティア歓迎
2歳〜100歳 · 全性別 · 2026/09/28更新 · NCT01276470Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- On Site Clinical Solutions Llc, Charlotte
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07621809A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
被験者募集中第2/3相
6歳〜75歳 · 全性別 · 2026/09/17更新 · NCT06154252Daratumumab in Primary Antiphospholipid Syndrome
- Duke University, Durham
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/09/16更新 · NCT05671757A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- East Carolina University, Greenville
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/11更新 · NCT07059000A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Duke University Hospital, Durham
- East Carolina University, Greenville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- UNC Chapel Hill, Chapel Hill
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/26更新 · NCT06121297RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Duke University, Durham
被験者募集中第2/3相
18歳〜75歳 · 全性別 · 2026/08/17更新 · NCT06328777A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- Duke University Medical Center, Durham
被験者募集中第3相
12歳以上 · 全性別 · 2026/08/06更新 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-108, Greenville
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/07/31更新 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1020, Chapel Hill
- Site Number - 1013, Durham
- Site Number - 1044, Raleigh
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/07/30更新 · NCT07039916A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/14更新 · NCT07115745A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
被験者募集中第1相
12歳〜70歳 · 全性別 · 2026/05/22更新 · NCT06308978Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- Duke University, Durham
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 女性 · 2026/01/08更新 · NCT03276923ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。